Methodology :

Objective: To evaluate the acceptability of the product on the face, confirming the absence of comedogenic/ acnegenic potential, AEs and cutaneous and ocular discomfort sensations​

​

Population: 33 adult subjects, mean age: 29 years old, phototype I to V​

Acne prone subjects, presenting showing facial acne spots, lack of homogeneity/ uniformity in skin tone, enlarged pores, oily skin on the face ​

Design (application): ​
Once or twice daily application on the face, for 28 days​

​

Evaluations: ​

• Tolerance: dermatological and ophthalmological assessments​

• Efficacy evaluation through self-Assessment questionnaires​

• Evaluation of clinical efficacy by a dermatologist (assessment of acne severity (IGA), acne spots - PIH, pore opening, texture and homogeneity of skin tone)​

• Skin oil assessments: Sebumeter®​

• Evaluation of the product efficacy in inflammatory and non-inflammatory acne vulgaris: by counting lesions​

After 4 weeks of use (D29), statistically significant decrease of Microcysts*: -64%, for 73% of subjects

Conclusion: 

• - 91 % sebum form the first application​

• - 64% of whiteheads after 4 weeks of use